WHO WE ARE

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian life sciences company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1’s proprietary technology platform is based on novel tumour markers with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes two development-stage BARD1 autoantibody tests for early detection of lung and ovarian cancers, and a research-stage cancer vaccine under evaluation for treatment of cancer. BARD1 is committed to transforming the early detection and prevention of cancer to help improve patients’ lives.

NEWS
TECHNOLOGY

PIPELINE

BARD1 is developing a pipeline of
cancer diagnostic and therapeutic
products based on its proprietary
BARD1 technology.

Our lead product the BARD1
Lung Cancer Test